Literature DB >> 22244930

Meta-analysis for cyclin E in lung cancer survival.

Li-nian Huang1, Dong-sheng Wang, Yu-qing Chen, Wei Li, Feng-dan Hu, Bei-lei Gong, Cheng-Ling Zhao, Wei Jia.   

Abstract

BACKGROUND: To assess the prognosis value of cyclin E expression in survival of patients with lung cancer (LC), we performed a systematic review of the literature with meta-analysis.
METHODS: Electronic databases were used to identify published studies before August 2011. Pooled hazard ratio (HR) with 95% confidence interval (95% CI) was used to estimate the strength of the association of cyclin E expression with survival of LC patients. Heterogeneity and publication bias were also assessed.
RESULTS: Fourteen studies (2606 cases) were eligible and subjected to analysis. Cyclin E over-expression was found to be a strong predictor of poor prognosis in LC patients (HR: 1.38, 95% CI: 1.07-1.79; P=0.014). When only non-small cell lung cancer (NSCLC) was considered, the combined HR was 1.53 (95% CI: 1.19-1.97, P=0.001). A significant association was also evident when the analysis was limited to studies involving adenocarcinoma (AD), but not squamous cell carcinoma (SQ). Publication bias was absent. Sensitivity analyses suggested that the summary statistics obtained should approximate the actual average. Copyright Â
© 2012 Elsevier B.V. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22244930     DOI: 10.1016/j.cca.2011.12.020

Source DB:  PubMed          Journal:  Clin Chim Acta        ISSN: 0009-8981            Impact factor:   3.786


  19 in total

1.  TRIM31 is downregulated in non-small cell lung cancer and serves as a potential tumor suppressor.

Authors:  Hui Li; Yi Zhang; Yue Zhang; Xue Bai; Yang Peng; Ping He
Journal:  Tumour Biol       Date:  2014-02-25

2.  Prognostic value of cyclin B in endometrial endometrioid adenocarcinoma.

Authors:  Simi Santala; Anne Talvensaari-Mattila; Ylermi Soini; Markku Santala
Journal:  Tumour Biol       Date:  2014-10-15

3.  The alpha-fetoprotein (AFP) third domain: a search for AFP interaction sites of cell cycle proteins.

Authors:  G J Mizejewski
Journal:  Tumour Biol       Date:  2016-07-22

Review 4.  New insights into the functions and localization of the homeotic gene CDX2 in gastric cancer.

Authors:  Lin-Hai Yan; Wei-Yuan Wei; Yu-Bo Xie; Qiang Xiao
Journal:  World J Gastroenterol       Date:  2014-04-14       Impact factor: 5.742

5.  Strong expression of cyclin B2 mRNA correlates with a poor prognosis in patients with non-small cell lung cancer.

Authors:  Shinogu Takashima; Hajime Saito; Naoko Takahashi; Kazuhiro Imai; Satoshi Kudo; Maiko Atari; Yoshitaro Saito; Satoru Motoyama; Yoshihiro Minamiya
Journal:  Tumour Biol       Date:  2013-12-28

6.  Prognostic significance of Cdx2 immunohistochemical expression in gastric cancer: a meta-analysis of published literatures.

Authors:  Xiao-Tong Wang; Wei-Yuan Wei; Fan-Biao Kong; Chao Lian; Wen Luo; Qiang Xiao; Yu-Bo Xie
Journal:  J Exp Clin Cancer Res       Date:  2012-11-26

7.  miR-497 and miR-34a retard lung cancer growth by co-inhibiting cyclin E1 (CCNE1).

Authors:  Zhiyuan Han; Yanbin Zhang; Qiaoyuan Yang; Binbin Liu; Jianjun Wu; Yajie Zhang; Chengfeng Yang; Yiguo Jiang
Journal:  Oncotarget       Date:  2015-05-30

8.  RNA-dependent protein kinase (PKR) depletes nutrients, inducing phosphorylation of AMP-activated kinase in lung cancer.

Authors:  Chengcheng Guo; Chuncheng Hao; RuPing Shao; Bingliang Fang; Arlene M Correa; Wayne L Hofstetter; Jack A Roth; Carmen Behrens; Neda Kalhor; Ignacio I Wistuba; Stephen G Swisher; Apar Pataer
Journal:  Oncotarget       Date:  2015-05-10

9.  Online survival analysis software to assess the prognostic value of biomarkers using transcriptomic data in non-small-cell lung cancer.

Authors:  Balázs Győrffy; Pawel Surowiak; Jan Budczies; András Lánczky
Journal:  PLoS One       Date:  2013-12-18       Impact factor: 3.240

10.  Cyclin E involved in early stage carcinogenesis of esophageal adenocarcinoma by SNP DNA microarray and immunohistochemical studies.

Authors:  Zhongren Zhou; Santhoshi Bandla; Jiqing Ye; Yinglin Xia; Jianwen Que; James D Luketich; Arjun Pennathur; Jeffrey H Peters; Dongfeng Tan; Tony E Godfrey
Journal:  BMC Gastroenterol       Date:  2014-04-17       Impact factor: 3.067

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.